Viyash Scientific Q2 FY27 Revenue Rises 16.2% to ₹987.94 Crore

Viyash Scientific Limited reported consolidated revenue of ₹987.94 crore for Q2 FY27, up 16.2% year-on-year and 4.4% sequentially, while consolidated net profit rose 16.1% year-on-year to ₹84.65 crore for the quarter ended September 30, 2026. The Board approved the unaudited results on November 13, 2026.

What did Viyash Scientific report for Q2 FY27?

Viyash Scientific reported consolidated revenue from operations of ₹987.94 crore and profit after tax of ₹84.65 crore in Q2 FY27. Revenue increased 4.4% from the preceding quarter and 16.2% from the corresponding quarter a year earlier. Net profit increased 6.8% sequentially and 16.1% year-on-year.

The reported numbers cover the quarter from July through September 2026. The company did not report consolidated exceptional items for the quarter, meaning the stated quarterly profit was not affected by any separately disclosed exceptional charge or gain in the consolidated results.

How were the Q2 FY27 results approved?

Viyash Scientific's Board of Directors considered and approved the unaudited standalone and consolidated financial results at its meeting on November 13, 2026. The approval covered both the quarter and the half year ended September 30, 2026.

The Board also considered the Independent Auditor's Limited Review Report alongside the financial statements. The auditors issued unmodified limited-review conclusions for the quarter and half year. An unmodified conclusion indicates that the auditors did not identify a matter requiring modification of their conclusion based on their limited-review procedures.

The company, formerly known as Sequent Scientific Limited, released the statements after the end of the September quarter. The Q2 FY27 earnings call is scheduled for November 14, 2026, at 11:00 AM IST, providing the next disclosed forum for management commentary on the reported period.

What do the standalone and half-year figures show?

Viyash Scientific's standalone business recorded revenue from operations of ₹390.65 crore and profit after tax of ₹23.36 crore in Q2 FY27. These figures are separate from the consolidated numbers, which include the financial performance of subsidiaries and other entities consolidated under the applicable accounting framework.

For the first half of FY27, standalone revenue from operations was ₹744.34 crore and standalone profit after tax was ₹44.28 crore. Consolidated revenue from operations for the half year was ₹1,934.30 crore, while consolidated profit after tax was ₹163.94 crore.

The gap between standalone and consolidated revenue is material. For investors, this makes the consolidated statement the broader measure of the group's reported scale, while the standalone statement reflects the parent entity's own financial performance.

How did amalgamation affect the reported financial statements?

Viyash Scientific disclosed that prior-period comparatives were restated for the amalgamation. Restatement of comparative figures is intended to align earlier-period data with the accounting treatment applied following the amalgamation, which is relevant when readers assess period-to-period changes.

While Q2 FY27 had no consolidated exceptional items, the first half included ₹2.95 crore of amalgamation-related expenses. The distinction matters because the half-year profit incorporates that disclosed expense, whereas the quarterly consolidated result did not include exceptional items.

The company did not disclose a separate quarterly exceptional item in the information provided. As a result, comparisons between Q2 figures can focus on the reported movements in revenue and profit, while half-year comparisons should account for the amalgamation-related expense and restated comparatives.

What does the result mean for investors and operations?

Viyash Scientific's results show continued growth in both consolidated revenue and profit against the prior quarter and the prior-year quarter. Revenue growth of 16.2% and profit growth of 16.1% year-on-year indicate that the reported top-line and bottom-line increases were closely aligned during Q2 FY27.

The result also provides a current data point against management's stated FY27 objective of ₹4,000 crore in revenue and a 20% EBITDA margin. The company has not provided Q2 EBITDA or an EBITDA margin in the results information supplied, so progress on the margin component cannot be assessed from these reported figures alone.

For shareholders, the scheduled earnings call is the immediate event to monitor for management's discussion of the half-year performance, the restated comparative numbers and the stated FY27 operating targets. No new information on customer impact, site operations or workforce changes was disclosed with the financial results provided.

Conclusion

Viyash Scientific closed Q2 FY27 with consolidated revenue of ₹987.94 crore and net profit of ₹84.65 crore, with both metrics higher sequentially and year-on-year. The Board's approval of the unaudited statements and the auditors' unmodified limited-review conclusions provide the formal basis for the reported quarter and half-year figures.

The next scheduled item is the November 14, 2026 earnings call. Investors will watch for management's comments on the ₹4,000 crore FY27 revenue objective, the 20% EBITDA-margin target, and the implications of amalgamation-related accounting and restated comparatives for interpreting future results.